Real Chemistry has partnered with Corval to add a commercialization planning and launch platform to its offering. The arrangement brings together Corval’s software for generating commercialization road maps and Real Chemistry’s services and data insights.
Since setting up shop in 2018, Corval has worked to help companies identify the path to market. Users of its platform answer questions about topics such as the timing of clinical trial results and the experience of their teams. The platform recommends objectives based on the assumptions and generates a three- to five-year road map of what the company needs to do—and when—to get the drug to market.
The idea is to define the strategies, objectives and cross-functional activities a company will need to start and show what resources the team will need to follow the road map. Corval creates an itemized budget and hiring plan that outlines head count, target salaries and operational fees.
Corval has pitched its platform at early- to midstage biopharma companies. Real Chemistry, which offers services to understand and engage patients and healthcare professionals, sees the platform as a good fit for some of its clients, which run the gamut from series A startups to big commercial businesses.
Ericka McKenna, integrated commercial solutions officer at Real Chemistry, said in a statement that the platform is “a critical tool to further enhance the efficiency of commercial planning and provide the deep strategic insights that are crucial for navigating the complex biotech landscape.”
The partnership is the latest in a series of moves by Real Chemistry to expand its capabilities. Over the past year, the company has acquired Avant Healthcare to boost its healthcare professional messaging and opened a second office in the U.K. One asset went the other way last month, when Real Chemistry investor New Mountain Capital established omnichannel marketing unit Swoop as a standalone business.